Literature DB >> 25472670

Suitability of circulating miRNAs as potential prognostic markers in colorectal cancer.

Jonas Ristau1, Jürgen Staffa1, Petra Schrotz-King1, Biljana Gigic1, Karen W Makar2, Michael Hoffmeister3, Herrmann Brenner4, Alexis Ulrich5, Martin Schneider5, Cornelia M Ulrich6, Nina Habermann7.   

Abstract

miRNAs are crucial in cellular processes and have been shown to be abnormally expressed in cancer tissue and the circulation. Circulating miRNAs may serve as a novel class of minimally invasive biomarkers for prognosis. Within a first methodologic study, we evaluated the miRNA profile kinetics in the plasma of patients with colorectal cancer after surgical tumor removal to identify potential suitability as prognostic biomarkers. This pilot study is based on the ColoCare Study, a cohort study of newly diagnosed patients with stage I-IV colorectal cancer. Colorectal cancer pre- and postsurgical blood (2-7 days after surgery) and 6 months follow-up blood from 35 patients were examined and candidate miRNAs were investigated in the plasma. miRNA levels were measured by two-step qRT-PCR. Statistical analysis was performed using log-transformed normalized CT values using SAS 9.3. Comparing pre- and postsurgical miRNA levels revealed a statistically significant decrease of nine circulating miRNAs after surgery (miR92a, miR18a, miR320a, miR106a, miR16-2, miR20a, miR223, miR17, and miR143). Analyses of plasma levels over all three time points demonstrated a statistically significant decrease from presurgery to postsurgery and re-increase from postsurgery to the six months follow-up time point of four circulating miRNAs (miR92a, miR320a, miR106a, and miR18a). We were able to show for the first time that in plasma miRNA profiles change within days after colorectal cancer surgery. Our results underscore the role of the investigated miRNAs in colorectal cancer and their potential utility as prognostic biomarkers. See all the articles in this CEBP Focus section, "Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology." ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25472670      PMCID: PMC5699859          DOI: 10.1158/1055-9965.EPI-14-0556

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  35 in total

Review 1.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis.

Authors:  Nobuyoshi Kosaka; Haruhisa Iguchi; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2010-07-07       Impact factor: 6.716

2.  Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases.

Authors:  Vlastimil Kulda; Martin Pesta; Ondrej Topolcan; Vaclav Liska; Vladislav Treska; Alan Sutnar; Karel Rupert; Marie Ludvikova; Vaclav Babuska; Lubos Holubec; Radim Cerny
Journal:  Cancer Genet Cytogenet       Date:  2010-07-15

3.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).

Authors:  Evan M Kroh; Rachael K Parkin; Patrick S Mitchell; Muneesh Tewari
Journal:  Methods       Date:  2010-02-08       Impact factor: 3.608

4.  Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.

Authors:  Xing-xiang Pu; Guo-liang Huang; Hong-qiang Guo; Cheng-cheng Guo; Haoran Li; Shen Ye; Suxia Ling; Li Jiang; Ying Tian; Tong-yu Lin
Journal:  J Gastroenterol Hepatol       Date:  2010-10       Impact factor: 4.029

5.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Authors:  Mattia Boeri; Carla Verri; Davide Conte; Luca Roz; Piergiorgio Modena; Federica Facchinetti; Elisa Calabrò; Carlo M Croce; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

6.  Diagnostic and prognostic microRNAs in stage II colon cancer.

Authors:  Troels Schepeler; Jørgen T Reinert; Marie S Ostenfeld; Lise L Christensen; Asli N Silahtaroglu; Lars Dyrskjøt; Carsten Wiuf; Frank J Sørensen; Mogens Kruhøffer; Søren Laurberg; Sakari Kauppinen; Torben F Ørntoft; Claus L Andersen
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

8.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

9.  Deregulated expression of miR-106a predicts survival in human colon cancer patients.

Authors:  Raquel Díaz; Javier Silva; José M García; Yolanda Lorenzo; Vanesa García; Cristina Peña; Rufo Rodríguez; Concepción Muñoz; Fernando García; Félix Bonilla; Gemma Domínguez
Journal:  Genes Chromosomes Cancer       Date:  2008-09       Impact factor: 5.006

10.  MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression.

Authors:  B Diosdado; M A van de Wiel; J S Terhaar Sive Droste; S Mongera; C Postma; W J H J Meijerink; B Carvalho; G A Meijer
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more
  15 in total

Review 1.  MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer.

Authors:  Zhipin Liang; Yaguang Xi
Journal:  Chin J Nat Med       Date:  2016-12

2.  Discovery of novel plasma proteins as biomarkers for the development of incisional hernias after midline incision in patients with colorectal cancer: The ColoCare study.

Authors:  Jürgen Böhm; Frank Pianka; Nina Stüttgen; Junghyun Rho; Biljana Gigic; Yuzheng Zhang; Nina Habermann; Petra Schrotz-King; Clare Abbenhardt-Martin; Lin Zielske; Paul D Lampe; Alexis Ulrich; Markus K Diener; Cornelia M Ulrich
Journal:  Surgery       Date:  2016-10-13       Impact factor: 3.982

3.  Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b, 26b, 18a and 155, and Their Involving Genes in Mice Colon Cancer.

Authors:  Zahra Heydari; Mahdi Rahaie; Ali Mohammad Alizadeh; Shahram Agah; Solmaz Khalighfard; Sahar Bahmani
Journal:  Probiotics Antimicrob Proteins       Date:  2019-12       Impact factor: 4.609

4.  Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer.

Authors:  Kunitoshi Shigeyasu; Yoshinaga Okugawa; Shusuke Toden; C Richard Boland; Ajay Goel
Journal:  Clin Cancer Res       Date:  2016-08-23       Impact factor: 12.531

5.  The ColoCare Study: A Paradigm of Transdisciplinary Science in Colorectal Cancer Outcomes.

Authors:  Cornelia M Ulrich; Biljana Gigic; Graham A Colditz; Jane C Figueiredo; William M Grady; Christopher I Li; David Shibata; Erin M Siegel; Adetunji T Toriola; Alexis Ulrich; Jürgen Böhm; Jennifer Ose; Richard Viskochil; Martin Schneider
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-12-06       Impact factor: 4.254

Review 6.  LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer.

Authors:  Arunoday Bhan; Subhrangsu S Mandal
Journal:  Biochim Biophys Acta       Date:  2015-07-21

7.  Associations of branched-chain amino acids with parameters of energy balance and survival in colorectal cancer patients: Results from the ColoCare Study.

Authors:  Mahmoud Delphan; Tengda Lin; David B Liesenfeld; Johanna Nattenmüller; Jürgen T Böhm; Biljana Gigic; Nina Habermann; Lin Zielske; Petra Schrotz-King; Martin Schneider; Alexis Ulrich; Hans-Ulrich Kauczor; Cornelia M Ulrich; Jennifer Ose
Journal:  Metabolomics       Date:  2018-01-31       Impact factor: 4.290

8.  Oncogenic role of microRNA‑20a in human uveal melanoma.

Authors:  Jinzi Zhou; Jian Jiang; Shuhong Wang; Xiaobo Xia
Journal:  Mol Med Rep       Date:  2016-06-23       Impact factor: 2.952

Review 9.  Involvement and Clinical Aspects of MicroRNA in Osteosarcoma.

Authors:  Ram Mohan Ram Kumar; Aleksandar Boro; Bruno Fuchs
Journal:  Int J Mol Sci       Date:  2016-06-03       Impact factor: 5.923

10.  The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Authors:  Mitchell S Stark; Kerenaftali Klein; Benjamin Weide; Lauren E Haydu; Annette Pflugfelder; Yue Hang Tang; Jane M Palmer; David C Whiteman; Richard A Scolyer; Graham J Mann; John F Thompson; Georgina V Long; Andrew P Barbour; H Peter Soyer; Claus Garbe; Adrian Herington; Pamela M Pollock; Nicholas K Hayward
Journal:  EBioMedicine       Date:  2015-05-12       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.